Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy

Hyeong Cheon Park, Zhong Gao Xu, Sorae Choi, Young Suck Goo, Shin Wook Kang, Kyu Hun Choi, Sung Kyu Ha, Ho Yung Lee, Dae Suk Han

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)


Background. Transforming growth factor-β1 (TGF-β1) is the major profibrotic cytokine involved in many renal diseases, and urinary TGF-β1 reflects intrarenal TGF-β1 production. Urinary TGF-β1 excretion is reported to be significantly increased in patients with immunoglobulin A (IgA) nephropathy. The aim of the present study was to compare the effects of losartan and amlodipine on proteinuria, as well as on serum and urine TGF-β1 levels in IgA nephropathy patients with hypertension and proteinuria. Methods. The initial 4 week washout period was followed by 12 weeks of active treatment, in which patients were randomized to once-daily treatment with losartan 50 mg (group 1, n = 20) or amlodipine 5 mg (group 2, n = 16). Urinary protein and TGF-β1 excretion, serum TGF-β1 and other clinical parameters were determined at baseline and during 12 weeks of active treatment. Results. Both treatments controlled blood pressure (BP) to a similar degree, and renal function and other biochemical parameters did not change during the study period. Urinary protein and TGF-β1 excretions were significantly elevated in IgA nephropathy patients. Losartan significantly reduced urinary protein (from 2.3 ± 1.5 g/day at baseline to 1.2 ± 1.5 g/day at 12 weeks, P < 0.05) and urinary TGF-β1 excretion (from 31.2 ± 14.0 pg/mg creatinine at baseline to 22.1 ± 13.5 pg/mg creatinine at 12 weeks, P < 0.05). In contrast, amlodipine had no affect on urinary protein and TGF-β1 excretion. Both losartan and amlodipine failed to reduce serum TGF-β1 levels. Conclusion. Losartan and amlodipine, with similar control of BP, showed different effects on urine protein or TGF-β1 excretion. Whereas losartan improved both urinary parameters, amlodipine did not. These differences might be important for the management of IgA nephropathy.

Original languageEnglish
Pages (from-to)1115-1121
Number of pages7
JournalNephrology Dialysis Transplantation
Issue number6
Publication statusPublished - 2003 Jun 1

Bibliographical note

Funding Information:
Acknowledgements. This study was partially supported by Brain Korea 21 project for Medical Sciences, Yonsei University and in part by a clinical research grant by MSD Korea. This work was presented at the XXXIX Congress of the ERA-EDTA and has been published in abstract form in Nephrology Dialysis Transplantation.

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Transplantation


Dive into the research topics of 'Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy'. Together they form a unique fingerprint.

Cite this